Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease

Table 3 Comparison of the diagnostic value among fibrosis-4 index, nonalcoholic fatty liver disease fibrosis score, aspartate aminotransferase to platelet ratio index, and body mass index, aspartate aminotransferase/alanine aminotransferase ratio, diabetes score in metabolic associated fatty liver disease

	Cutoffs	AUROC	Accuracy, %	Advanced fibrosis being missed, %1	Sensitivity, %	Specificity, %	PPV, %	NPV, %	Youden index
FIB-4	1.05	0.736	66.2	20.3	73.7	61.7	53.5	79.7	0.354
	1.30		68.1	25.4	57.7	74.3	57.3	74.6	0.320
	1.45		68.8	26.5	52.6	78.5	59.4	73.5	0.311
	2.67		66.2	34.1	17.3	95.4	69.2	65.9	0.127
	3.25		66.7	34.4	14.1	98.1	81.5	65.6	0.122
NFS	-2.100	0.724	68.1	20.9	70.5	66.7	55.8	79.1	0.372
	-1.455		66.2	29.5	44.9	78.9	56.0	70.6	0.238
	0.676		63.8	36.5	4.5	99.2	77.8	63.5	0.037
APRI	0.42	0.671	58.3	20.0	81.4	44.4	46.7	80.0	0.258
	0.50		59.2	24.7	71.2	52.5	47.2	75.3	0.237
	1.50		63.3	34.6	22.4	87.7	52.2	65.4	0.101
BARD	2	0.609	64.5	30.8	41.7	78.2	53.3	69.2	0.199

Best cutoff value in bold.

¹The percentage was calculated as the number of advanced fibrosis being missed diagnosed/the number of patients who were diagnosed as no advanced fibrosis by the non-invasive score × 100%. APRI: Aspartate aminotransferase to platelet ratio index; AUROC: Area under the receiver operating characteristic curve; BARD: Body mass index, aspartate aminotransferase/alanine aminotransferase ratio, diabetes score; FIB-4: Fibrosis-4 index; NFS: Nonalcoholic fatty liver disease fibrosis score; NPV: Negative predictive value; PPV: Positive predictive value.